Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms. Th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Jacobsen, Kirstine, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Teixidó, Cristina, Karachaliou, Niki, Pedersen, Martin Haar, Castellví, Josep, Garzón, Mónica, Codony-Servat, Carles, Codony-Servat, Jordi, Giménez-Capitán, Ana, Drozdowskyj, Ana, Viteri, Santiago, Larsen, Martin R., Lassen, Ulrik, Felip, Enriqueta, Bivona, Trever G., Ditzel, Henrik J., Rosell, Rafael
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5583255/
https://ncbi.nlm.nih.gov/pubmed/28871105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-00450-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados